Efficacy of Filgrastim in Managing Chemotherapy-Induced Febrile Neutropenia in Iraqi Patients with Non-Small Cell Lung Cancer
Fatima Adnan Alzubaidi, Enass Najem Oubaid,
Ammar A. H. Azzam, Mohammed Sh. Sachit,
Hiba Falih abdulhussien, Fatima Mohammed hadi, Saif M. Hassan
Filgrastim, a recombinant human granulocyte colony-stimulating factor, has been intensively researched as a systemic treatment for neutropenia, notably in cancer patients receiving myelosuppressive chemotherapy. The use of filgrastim has demonstrated considerable benefits in reducing the frequency and duration of febrile neutropenia, as well as in supporting the maintenance of chemothera-py dose intensity. The research findings that multiple doses regime of filgrastim has significant benefits observed in reducing the incidence and duration of fe-brile neutropenia, as well as in supporting the maintenance of chemotherapy dose intensity, highlight its valuable role in improving the quality of life and treatment outcomes for patients undergoing myelosuppressive chemotherapy. In conclusion, the research on multiple doses regime of filgrastim provides solid evidence for its usefulness in controlling neutropenia-related problems in cancer patients.
Keywords: NSCLC, Neutropenia, Filgrastim, chemotherapy, Granulocyte colony-stimulating factor
